

Supplementary materials for “What do the Clinical Features of Positive Nontuberculous Mycobacteria Isolates from Patients with HIV/AIDS in China reveal? A Systematic Review and meta-analysis”.

Table S1. All original data

Table S2. Database search strategies

Table S3. The Agency for Healthcare Research and Quality (AHRQ) Methodology Checklist for Cross-Sectional Study

Table S4. The Newcastle-Ottawa Scale (NOS) for cohort study

Table S5. The Newcastle-Ottawa Scale (NOS) for case-control study

Table S6. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case series/case reports

Table S7. Quality assessment of the included studies

Table S8. Subgroup analyses of positive NTM isolates from patients with HIV/AIDS in different region

Table S9. Subgroup analyses of positive NTM isolates from patients with HIV/AIDS in sample size per study

Table S1. All original data

Gender distribution	Study	Event	Total
	Song et al., 2011	4	5
	Ding et al., 2022	62	71
	Wang et al., 2017	28	33
	Wu et al., 2017	28	31
	Cao et al., 2021	38	43
	Jiang et al., 2014	13	13
	Meng et al., 2018	19	29
	R. Lan et al., 2011	82	102
	Yin et al., 2015	77	97
	Zhou et al., 2013	106	135
	Wang et al., 2022	8	9
	Li et al., 2016	24	27
	Huang et al., 2021	16	22
	Li, 2018	50	50
	Zhu et al., 2013	27	27
	Sun et al., 2019	329	377
	Tian at al., 2022	161	169
	Wang et al., 2019	50	59
	Zhang et al., 2021	69	90
	Li et al., 2018	16	23
	Liu et al., 2021	34	44
	Chou et al., 2011	21	22
	Chiang et al., 2020	86	94
Species distribution			
<i>Mycobacterium avium</i> complex	Study	Event	Total
	Song et al., 2011	4	5
	Ding et al., 2022	68	71
	Wu et al., 2017	15	31
	Cao et al., 2021	24	43
	R. Lan et al., 2011	55	102
	Huang et al., 2022	7	11
	Zhou et al., 2013	79	135
	Wang et al., 2021	78	97
	Huang et al., 2021	10	22
	Sun et al., 2019	33	102
	Wang et al., 2019	31	59
	Zhang et al., 2021	73	90
	Liu et al., 2021	24	44
	Chou et al., 2011	21	22
<i>Mycobacterium abscessus</i> complex	Study	Event	Total
	Wu et al., 2017	2	31

	Cao et al., 2021	1	43
	R. Lan et al., 2011	3	102
	Zhou et al., 2013	4	135
	Wang et al., 2021	1	97
	Huang et al., 2021	3	22
	Wang et al., 2019	8	59
	Zhang et al., 2021	4	90
	Liu et al., 2021	3	44
	Chou et al., 2011	0	22
<i>Mycobacterium kansasii</i>	Study	Event	Total
	Ding et al., 2022	3	71
	Wu et al., 2017	4	31
	Cao et al., 2021	2	43
	R. Lan et al., 2011	8	102
	Zhou et al., 2013	10	135
	Wang et al., 2021	7	97
	Sun et al., 2019	25	102
	Wang et al., 2019	16	59
	Zhang et al., 2021	6	90
	Liu et al., 2021	5	44
	Chou et al., 2011	0	22
<i>Mycobacterium gordonae</i>	Study	Event	Total
	Wu et al., 2017	1	31
	Cao et al., 2021	3	43
	R. Lan et al., 2011	9	102
	Zhou et al., 2013	10	135
	Wang et al., 2021	5	97
	Huang et al., 2021	6	22
	Sun et al., 2019	29	102
	Zhang et al., 2021	2	90
	Liu et al., 2021	3	44
Other NTM species*	Study	Event	Total
	Song et al., 2011	1	5
	Wu et al., 2017	9	31
	Cao et al., 2021	13	43
	R. Lan et al., 2011	27	102
	Huang et al., 2022	4	11
	Zhou et al., 2013	32	135
	Wang et al., 2021	6	97
	Huang et al., 2021	3	22
	Sun et al., 2019	15	102
	Wang et al., 2019	4	59
	Zhang et al., 2021	5	90

	Liu et al., 2021	9	44
	Chou et al., 2011	1	22
Clinical symptoms			
Fever	Study	Event	Total
	Ding et al., 2022	54	71
	Wu et al., 2017	25	31
	Cao et al., 2021	34	43
	Jiang et al., 2014	10	13
	Meng et al., 2008	26	36
	Meng et al., 2018	24	29
	Zhang et al., 2011	42	82
	Yin et al., 2015	70	97
	Wang et al., 2022	5	9
	Li et al., 2016	21	27
	Deng et al., 2013	24	63
	Wang et al., 2019	36	59
	Li et al., 2018	19	23
	Liu et al., 2021	30	44
	Chou et al., 2011	10	22
	Chiang et al., 2020	65	94
Cough or expectoration	Study	Event	Total
	Ding et al., 2022	24	71
	Wu et al., 2017	25	31
	Cao et al., 2021	31	43
	Meng et al., 2008	15	36
	Meng et al., 2018	19	29
	Zhang et al., 2011	52	82
	Yin et al., 2015	93	97
	Li et al., 2016	22	27
	Deng et al., 2013	21	63
	Wang et al., 2019	47	59
	Li et al., 2018	22	23
	Liu et al., 2021	39	44
	Chou et al., 2011	8	22
	Chiang et al., 2020	59	94
Dyspnea	Study	Event	Total
	Ding et al., 2022	9	71
	Cao et al., 2021	18	43
	Meng et al., 2018	6	29
	Yin et al., 2015	71	97
	Li et al., 2016	10	27
	Deng et al., 2013	7	63
	Wang et al., 2019	20	59

	Liu et al., 2021	22	44
Chest pain	Study	Event	Total
	Ding et al., 2022	7	71
	Yin et al., 2015	47	97
	Li et al., 2016	5	27
Abdominal pain or diarrhea	Study	Event	Total
	Ding et al., 2022	18	71
	Cao et al., 2021	14	43
	Meng et al., 2018	8	29
	Yin et al., 2015	36	97
	Wang et al., 2019	10	59
	Chou et al., 2011	6	22
	Chiang et al., 2020	26	94
Night sweats	Study	Event	Total
	Ding et al., 2022	6	71
	Zhang et al., 2011	16	82
	Wang et al., 2022	2	9
	Deng et al., 2013	13	63
	Li et al., 2018	9	23
	Chiang et al., 2020	13	94
Fatigue	Study	Event	Total
	Ding et al., 2022	23	71
	Wu et al., 2017	8	31
	Cao et al., 2021	12	43
	Meng et al., 2018	28	29
	Zhang et al., 2011	31	82
	Yin et al., 2015	58	97
	Li et al., 2016	9	27
	Deng et al., 2013	20	63
	Wang et al., 2019	9	59
	Chiang et al., 2020	19	94
Erythra	Study	Event	Total
	Jiang et al., 2014	9	13
	Wang et al., 2019	13	59
	Chou et al., 2011	2	22
Weight loss	Study	Event	Total
	Ding et al., 2022	10	71
	Wu et al., 2017	17	31
	Cao et al., 2021	3	43
	Meng et al., 2018	23	29
	Zhang et al., 2011	45	82
	Yin et al., 2015	69	97
	Wang et al., 2022	3	9

	Deng et al., 2013	19	63	
	Wang et al., 2019	17	59	
	Li et al., 2018	21	23	
	Chou et al., 2011	7	22	
	Chiang et al., 2020	46	94	
Hemoptysis	Study	Event	Total	
	5Cao et al., 2021	3	43	
	Zhang et al., 2011	4	82	
	Li et al., 2016	1	27	
	Deng et al., 2013	2	63	
Appetite loss	Study	Event	Total	
	Cao et al., 2021	14	43	
	Meng et al., 2018	27	29	
	Chiang et al., 2020	21	94	
Superficial lymphadenectasis	Study	Event	Total	
	Cao et al., 2021	8	43	
	Jiang et al., 2014	6	13	
	Meng et al., 2018	16	29	
	Yin et al., 2015	39	97	
	Wang et al., 2022	6	9	
	Li et al., 2016	11	27	
	Deng et al., 2013	12	63	
	Li, 2018	18	50	
	Zhu et al., 2013	11	27	
	Li et al., 2018	16	23	
	Laboratory tests			
ALB < 35 (g/L) ^b	Study	Event	Total	
	Ding et al., 2022	63	71	
	Cao et al., 2021	12	43	
	Wang et al., 2022	6	9	
	Li et al., 2018	9	23	
ESR > 20 (mm/h) ^b	Study	Event	Total	
	Song et al., 2011	5	5	
	Ding et al., 2022	68	71	
	Wang et al., 2019	44	59	
CRP > 6 (mg/L) ^b	Study	Event	Total	
	Ding et al., 2022	63	71	
	Wang et al., 2019	52	59	
	Liu et al., 2021	29	44	
Hemoglobin count (g/L)^a	Study	Mean	SD	Total
	Ding et al., 2022	78.70	14.60	71
	Wang et al., 2017	93.80	22.90	33
	Huang et al., 2022	91.79	32.23	11

	Huang et al., 2021	124.45	31.20	22
	Tian et al., 2022	87.11	28.04	169
CD4+ T cell count (pieces/μL)^a	Study	Mean	SD	Total
	Wang et al., 2017	112.32	230.16	33
	Huang et al., 2022	26.46	34.78	11
	Huang et al., 2021	13.25	7.48	22
	Li, 2018	42.63	6.28	50
	Tian et al., 2022	10.11	11.96	168
	Li et al., 2018	72.70	72.90	23
	Anemia^b	Study	Event	Total
Wu et al., 2017		21	31	
Cao et al., 2021		10	43	
Meng et al., 2018		9	29	
Wang et al., 2022		5	9	
Wang et al., 2019		51	59	
Li et al., 2018		16	23	
Liu et al., 2021		34	44	
CD4+ T cell count \leq 50 (pieces/μL)^b	Study	Event	Total	
	Song et al., 2011	2	5	
	Ding et al., 2022	62	71	
	Cao et al., 2021	31	43	
	Meng et al., 2008	31	36	
	Meng et al., 2018	23	29	
	R. Lan et al., 2011	53	74	
	Wang et al., 2022	3	9	
	Li et al., 2016	19	27	
	Deng et al., 2013	23	63	
	Wang et al., 2021	51	97	
	Zhu et al., 2013	27	27	
	Wang et al., 2019	50	59	
	Zhang et al., 2021	42	90	
CD4+ cell count 51–200 (pieces/μL)^b	Study	Event	Total	
	Song et al., 2011	3	5	
	Ding et al., 2022	8	71	
	Cao et al., 2021	10	43	
	Meng et al., 2008	4	36	
	Meng et al., 2018	6	29	
	R. Lan et al., 2011	15	74	
	Wang et al., 2022	5	9	
	Li et al., 2016	8	27	
	Deng et al., 2013	22	63	
	Wang et al., 2021	27	97	
	Zhu et al., 2013	0	27	

	Wang et al., 2019	9	59
	Zhang et al., 2021	36	90
CD4+ cell count > 200 (pieces/μL)^b	Study	Event	Total
	Song et al., 2011	0	5
	Ding et al., 2022	1	71
	Cao et al., 2021	2	43
	Meng et al., 2008	1	36
	Meng et al., 2018	0	29
	R. Lan et al., 2011	6	74
	Wang et al., 2022	1	9
	Li et al., 2016	0	27
	Deng et al., 2013	18	63
	Wang et al., 2021	19	97
	Zhu et al., 2013	0	27
	Wang et al., 2019	0	59
	Zhang et al., 2021	12	90
	Thoracic imaging manifestations		
Distribution of lesions			
Single lung involvement	Study	Event	Total
	Ding et al., 2022	9	71
	Jiang et al., 2014	0	13
	Meng et al., 2008	4	10
	Meng et al., 2018	10	29
	Yin et al., 2015	14	97
	Li, 2018	8	50
	Zhu et al., 2013	0	27
Bilateral lung involvement	Study	Event	Total
	Ding et al., 2022	54	71
	Jiang et al., 2014	13	13
	Meng et al., 2008	6	10
	Meng et al., 2018	15	29
	Yin et al., 2015	83	97
	Li, 2018	42	50
	Zhu et al., 2013	27	27
No abnormalities	Study	Event	Total
	Ding et al., 2022	8	71
	Wang et al., 2017	9	33
	Jiang et al., 2014	0	13
	Meng et al., 2008	0	10
	Meng et al., 2018	4	29
	Yin et al., 2015	0	97
	Huang et al., 2021	4	22
	Li, 2018	0	50

	Zhu et al., 2013	0	27
	Chiang et al., 2020	60	94
Changes of lesion morphology and density			
Patchy shadows	Study	Event	Total
	Ding et al., 2022	30	71
	Wu et al., 2017	25	31
	Jiang et al., 2014	4	13
	Yin et al., 2015	35	97
	Li, 2018	18	50
	Zhu et al., 2013	2	27
	Wang et al., 2019	25	59
	Li et al., 2018	16	23
Nodules	Study	Event	Total
	Song et al., 2011	3	5
	Ding et al., 2022	26	71
	Wu et al., 2017	11	31
	Jiang et al., 2014	8	13
	Yin et al., 2015	20	97
	Li, 2018	32	50
	Zhu et al., 2013	18	27
	Wang et al., 2019	19	59
	Li et al., 2018	9	23
	Chiang et al., 2020	11	94
Millet shadow	Study	Event	Total
	Ding et al., 2022	1	71
	Wang et al., 2017	4	33
	Wu et al., 2017	2	31
	Huang et al., 2021	5	22
	Li, 2018	0	50
	Zhu et al., 2013	0	27
	Wang et al., 2019	11	59
	Chiang et al., 2020	0	94
Cavitary lesion	Study	Event	Total
	Song et al., 2011	1	5
	Ding et al., 2022	2	71
	Wang et al., 2017	0	33
	Wu et al., 2017	7	31
	Jiang et al., 2014	2	13
	Meng et al., 2008	2	36
	Meng et al., 2018	5	29
	Yin et al., 2015	53	97
Deng et al., 2013	12	35	

	Huang et al., 2021	0	22
	Li, 2018	8	50
	Zhu et al., 2013	4	27
	Wang et al., 2019	7	59
	Chiang et al., 2020	7	94
Stripe shadow	Study	Event	Total
	Ding et al., 2022	21	71
	Wang et al., 2017	21	33
	Jiang et al., 2014	13	13
	Yin et al., 2015	41	97
	Li, 2018	31	50
	Zhu et al., 2013	17	27
Ground glass opacity	Study	Event	Total
	Ding et al., 2022	10	71
	Jiang et al., 2014	7	13
	Li, 2018	19	50
	Zhu et al., 2013	10	27
Bronchiectasis	Study	Event	Total
	Song et al., 2011	1	5
	Jiang et al., 2014	4	13
	Yin et al., 2015	35	97
	Li et al., 2016	18	27
	Li, 2018	17	50
	Zhu et al., 2013	9	27
Accompanying Signs			
Thoracic lymph node enlargement	Study	Event	Total
	Song et al., 2011	5	5
	Ding et al., 2022	51	71
	Wu et al., 2017	25	31
	Jiang et al., 2014	4	13
	Meng et al., 2018	5	29
	Yin et al., 2015	7	97
	Li, 2018	28	50
	Zhu et al., 2013	8	27
	Li et al., 2018	15	23
Abdominal lymph node enlargement	Study	Event	Total
	Ding et al., 2022	31	71
	Meng et al., 2018	5	29
	Li, 2018	9	50
Hydropericardium	Study	Event	Total
	Ding et al., 2022	10	71
	Wu et al., 2017	2	31
	Meng et al., 2018	3	29

	Wang et al., 2019	6	59	
	Li et al., 2018	6	23	
Hydrothorax	Study	Event	Total	
	Ding et al., 2022	15	71	
	Wu et al., 2017	9	31	
	Meng et al., 2018	2	29	
	Deng et al., 2013	4	35	
	Huang et al., 2021	0	22	
	Li, 2018	2	50	
	Zhu et al., 2013	1	27	
	Wang et al., 2019	10	59	
	Li et al., 2018	14	23	
	Chiang et al., 2020	2	94	
	Pleural thickening	Study	Event	Total
		Song et al., 2011	1	5
Ding et al., 2022		20	71	
Jiang et al., 2014		5	13	
Yin et al., 2015		13	97	
Li et al., 2016		3	27	
Li, 2018		4	50	
Zhu et al., 2013		2	27	
Treatment outcome				
Symptoms improve[†]	Study	Event	Total	
	Ding et al., 2022	45	71	
	Wang et al., 2017	28	33	
	Meng et al., 2008	13	36	
	Meng et al., 2018	23	29	
	Yin et al., 2015	67	97	
	Wang et al., 2022	8	9	
	Death	Study	Event	Total
Ding et al., 2022		2	71	
Wang et al., 2017		2	33	
Meng et al., 2008		3	36	
Meng et al., 2018		4	29	
Yin et al., 2015		9	97	
Wang et al., 2022		0	9	
Others[‡]		Study	Event	Total
	Ding et al., 2022	24	71	
	Wang et al., 2017	3	33	
	Meng et al., 2008	20	36	
	Meng et al., 2018	2	29	
	Yin et al., 2015	21	97	
	Wang et al., 2022	1	9	

NTM – nontuberculous mycobacterial, ALB – albumin, ESR – erythrocyte sedimentation Rate, CRP – C-reactive protein, SD – standard deviation

* All other NTM species accounted for less than the above four species.

†Symptom improve is defined as getting better after treatment during hospitalization.

‡Others include automatic discharge, transfer to another hospital, and no apparent improvement.

#14	#10 OR #11 OR #12 OR #13
#15	#3 OR #6 AND #9 AND #14
Embase	
#1	Emtree: 'human immunodeficiency virus'/exp
#2	Title or Abstract: 'human immunodeficiency virus' OR 'immunodeficiency virus, human' OR 'immunodeficiency viruses, human' OR 'virus, human immunodeficiency' OR 'viruses, human immunodeficiency' OR 'human immunodeficiency viruses' OR 'human t cell lymphotropic virus type iii' OR 'human t-cell lymphotropic virus type iii' OR 'human t-cell leukemia virus type iii' OR 'human t cell leukemia virus type iii' OR 'lav htlv iii' OR 'lymphadenopathy-associated virus' OR 'lymphadenopathy associated virus' OR 'lymphadenopathy-associated viruses' OR 'virus, lymphadenopathy-associated' OR 'viruses, lymphadenopathy-associated' OR 'human t lymphotropic virus type iii' OR 'human t-lymphotropic virus type iii' OR 'aids virus' OR 'aids viruses' OR 'virus, aids' OR 'viruses, aids' OR 'acquired immune deficiency syndrome virus' OR 'acquired immunodeficiency syndrome virus' OR 'HTLV-III'
#3	#1 OR #2
#4	Emtree: 'acquired immune deficiency syndrome'/exp
#5	Title or Abstract: 'immunologic deficiency syndrome, acquired' OR 'acquired immune deficiency syndrome' OR 'acquired immuno-deficiency syndrome' OR 'acquired immuno deficiency syndrome' OR 'acquired immuno-deficiency syndromes' OR 'immuno-deficiency syndrome, acquired' OR 'immuno-deficiency syndromes, acquired' OR 'syndrome, acquired immuno-deficiency' OR 'syndromes, acquired immuno-deficiency' OR 'immunodeficiency syndrome, acquired' OR 'acquired immunodeficiency syndromes' OR 'immunodeficiency syndromes, acquired' OR 'syndrome, acquired immunodeficiency' OR 'syndromes, acquired immunodeficiency' OR aids
#6	#4 OR #5
#7	Emtree: 'atypical mycobacteriosis'/exp
#8	Title or Abstract: 'mycobacterium, atypical' OR 'tuberculoid bacillus' OR 'atypical mycobacterium' OR 'atypical mycobacteria' OR 'mycobacteria, atypical' OR 'nontuberculous mycobacterium' OR 'non-tuberculous mycobacteria' OR 'mycobacterium szulgai' OR 'mycobacterium gordonae' OR 'mycobacterium duvalii' OR 'mycolicibacterium duvalii' OR 'mycobacterium flavescens' OR 'mycolicibacterium flavescens' OR 'mycobacterium gilvum' OR 'mycolicibacterium gilvum' OR 'mycobacterium obuense' OR 'mycolicibacterium obuense' OR 'mycobacterium terrae' OR 'mycolicibacter terrae'
#9	#7 OR #8
#10	Emtree: 'china'/exp
#11	Emtree: 'hong kong'/exp
#12	Emtree: 'macao'/exp
#13	Emtree: 'taiwan'/exp
#14	#10 OR #11 OR #12 OR #13
#15	#3 OR #6
#16	#9 AND #14 AND #15
Web of Science	
#1	Human Immunodeficiency Virus (Topic) or Immunodeficiency Virus, Human (Topic) or Immunodeficiency Viruses, Human (Topic) or Virus, Human Immunodeficiency (Topic) or Viruses, Human Immunodeficiency (Topic) or Human Immunodeficiency Viruses (Topic) or Human T Cell Lymphotropic Virus Type III (Topic) or Human T-Cell Lymphotropic Virus Type III (Topic) or Human T-Cell Leukemia Virus Type III (Topic) or Human

	T Cell Leukemia Virus Type III (Topic) or LAV-HTLV-III (Topic) or Lymphadenopathy-Associated Virus (Topic) or Lymphadenopathy Associated Virus (Topic) or Lymphadenopathy-Associated Viruses (Topic) or Virus, Lymphadenopathy-Associated (Topic) or Viruses, Lymphadenopathy-Associated (Topic) or Human T Lymphotropic Virus Type III (Topic) or Human T-Lymphotropic Virus Type III (Topic) or AIDS Virus (Topic) or AIDS Viruses (Topic) or Virus, AIDS (Topic) or Viruses, AIDS (Topic) or Acquired Immune Deficiency Syndrome Virus (Topic) or Acquired Immunodeficiency Syndrome Virus (Topic) or HTLV-III (Topic)
#2	Immunologic Deficiency Syndrome, Acquired (Topic) or Acquired Immune Deficiency Syndrome (Topic) or Acquired Immuno-Deficiency Syndrome (Topic) or Acquired Immuno Deficiency Syndrome (Topic) or Acquired Immuno-Deficiency Syndromes (Topic) or Immuno-Deficiency Syndrome, Acquired (Topic) or Immuno-Deficiency Syndromes, Acquired (Topic) or Syndrome, Acquired Immuno-Deficiency (Topic) or Syndromes, Acquired Immuno-Deficiency (Topic) or Immunodeficiency Syndrome, Acquired (Topic) or Acquired Immunodeficiency Syndromes (Topic) or Immunodeficiency Syndromes, Acquired (Topic) or Syndrome, Acquired Immunodeficiency (Topic) or Syndromes, Acquired Immunodeficiency (Topic) or AIDS (Topic)
#3	#1 OR #2
#4	Mycobacterium, Atypical (Topic) or Tuberculoid Bacillus (Topic) or Atypical Mycobacterium (Topic) or Atypical Mycobacteria (Topic) or Mycobacteria, Atypical (Topic) or Nontuberculous Mycobacterium (Topic) or Non-Tuberculous Mycobacteria (Topic) or Mycobacterium szulgai (Topic) or Mycobacterium gordonae (Topic) or Mycobacterium duvalii (Topic) or Mycolicibacterium duvalii (Topic) or Mycobacterium flavescens (Topic) or Mycolicibacterium flavescens (Topic) or Mycobacterium gilvum (Topic) or Mycolicibacterium gilvum (Topic) or Mycobacterium obuense (Topic) or Mycolicibacterium obuense (Topic) or Mycobacterium terrae (Topic) or Mycolicibacter terrae (Topic)
#5	#3 AND #4
#6	China (Topic) or Hong Kong (Topic) or Macau (Topic) or Taiwan (Topic)
#7	#5 AND #6
Cochrane Library	
#1	MeSH descriptor: [HIV] explode all trees
#2	(Human Immunodeficiency Virus) OR (Immunodeficiency Virus, Human) OR (Immunodeficiency Viruses, Human) OR (Virus, Human Immunodeficiency) OR (Viruses, Human Immunodeficiency) (Word variations have been searched)
#3	(Human Immunodeficiency Viruses) OR (Human T Cell Lymphotropic Virus Type III) OR (Human T-Cell Lymphotropic Virus Type III) OR (Human T-Cell Leukemia Virus Type III) OR (Human T Cell Leukemia Virus Type III) (Word variations have been searched)
#4	(LAV-HTLV-III) OR (Lymphadenopathy-Associated Virus) OR (Lymphadenopathy Associated Virus) OR (Lymphadenopathy-Associated Viruses) OR (Virus, Lymphadenopathy-Associated) (Word variations have been searched)
#5	(Viruses, Lymphadenopathy-Associated) OR (Human T Lymphotropic Virus Type III) OR (Human T-Lymphotropic Virus Type III) OR (AIDS Virus) OR (AIDS Viruses) (Word variations have been searched)
#6	(Virus, AIDS) OR (Viruses, AIDS) OR (Acquired Immune Deficiency Syndrome Virus) OR (Acquired Immunodeficiency Syndrome Virus) OR (HTLV-III) (Word variations have been searched)
#7	#1 OR #2 OR #3 OR #4 OR #5 OR #6
#8	MeSH descriptor: [Acquired Immunodeficiency Syndrome] explode all trees
#9	(Immunologic Deficiency Syndrome, Acquired) OR (Acquired Immune Deficiency Syndrome) OR (Acquired Immuno-Deficiency Syndrome) OR (Acquired Immuno Deficiency Syndrome) OR (Acquired Immuno-Deficiency Syndromes) (Word variations have been searched)

#10	(Immuno-Deficiency Syndrome, Acquired) OR (Immuno-Deficiency Syndromes, Acquired) OR (Syndrome, Acquired Immuno-Deficiency) OR (Syndromes, Acquired Immuno-Deficiency) OR (Immunodeficiency Syndrome, Acquired) (Word variations have been searched)
#11	(Acquired Immunodeficiency Syndromes) OR (Immunodeficiency Syndromes, Acquired) OR (Syndrome, Acquired Immunodeficiency) OR (Syndromes, Acquired Immunodeficiency) OR (AIDS) (Word variations have been searched)
#12	#8 OR #9 OR #10 OR #11
#13	MeSH descriptor: [Nontuberculous Mycobacteria] explode all trees
#14	(Mycobacterium, Atypical) OR (Tuberculoid Bacillus) OR (Atypical Mycobacterium) OR (Atypical Mycobacteria) OR (Mycobacteria, Atypical) (Word variations have been searched)
#15	(Nontuberculous Mycobacterium) OR (Non-Tuberculous Mycobacteria) OR (Mycobacterium szulgai) OR (Mycobacterium gordonae) OR (Mycobacterium duvalii) (Word variations have been searched)
#16	(Mycolicibacterium duvalii) OR (Mycobacterium flavescens) OR (Mycolicibacterium flavescens) OR (Mycobacterium gilvum) OR (Mycolicibacterium gilvum) (Word variations have been searched)
#17	(Mycolicibacterium duvalii) OR (Mycobacterium flavescens) OR (Mycolicibacterium flavescens) OR (Mycobacterium gilvum) OR (Mycolicibacterium gilvum) (Word variations have been searched)
#18	#13 OR #14 OR #15 OR #16 OR #17
#19	#7 OR #12
#20	MeSH descriptor: [China] explode all trees
#21	MeSH descriptor: [Hong Kong] explode all trees
#22	MeSH descriptor: [Macau] explode all trees
#23	MeSH descriptor: [Taiwan] explode all trees
#24	#20 OR #21 OR #22 OR #23
#25	#18 AND #19 AND #24
VIP Database	
#1	Title or Keywords = HIV OR human immunodeficiency virus OR human immunodeficiency viruses (In Chinese)
#2	Title or Keywords = Acquired Immune Deficiency Syndrome (In Chinese)
#3	#1 OR #2
#4	Title or Keywords = nontuberculous mycobacteria (In Chinese)
#5	#3 AND #4
China National Knowledge Infrastructure	
#1	Topic = HIV OR human immunodeficiency virus OR human immunodeficiency viruses (In Chinese)
#2	Topic = Acquired Immune Deficiency Syndrome (In Chinese)
#3	#1 OR #2
#4	Topic = nontuberculous mycobacteria (In Chinese)
#5	#3 AND #4
Wanfang Database	
#1	Topic = HIV OR human immunodeficiency virus OR human immunodeficiency viruses (In Chinese)
#2	Topic = Acquired Immune Deficiency Syndrome (In Chinese)
#3	#1 OR #2
#4	Topic = nontuberculous mycobacteria (In Chinese)

#5	#3 AND #4
SinoMed	
#1	"HIV"[Mesh] (In Chinese)
#2	Title/Abstract: Human Immunodeficiency Virus OR Lymphadenopathy Associated Virus OR AIDS Virus OR Acquired Immunodeficiency Syndrome Virus[Title/Abstract])) (In Chinese)
#3	#1 OR #2
#4	"Acquired Immunodeficiency Syndrome"[Mesh] (In Chinese)
#5	Title/Abstract: Acquired Immune Deficiency Syndrome OR Immunodeficiency Syndromes, Acquired OR AIDS (In Chinese)
#6	#4 OR #5
#7	"Nontuberculous Mycobacteria"[Mesh] (In Chinese)
#8	Mycobacterium, Atypical OR Nontuberculous Mycobacterium OR Mycobacterium szulgai OR Mycobacterium gordonae OR Mycobacterium duvalii OR Mycobacterium flavescens OR Mycobacterium gilvum OR Mycobacterium obuense OR Mycobacterium terrae (In Chinese)
#9	#7 OR #8
#10	#3 OR #6
#11	#9 AND #10

CNKI – China National Knowledge Infrastructure

*VIP Database and CNKI both have synonym extension function, Wanfang Database has subject term expansion function. SinoMed, CNKI, Wanfang, and VIP Database were restricted to searching Chinese studies.

Table S3. The Agency for Healthcare Research and Quality (AHRQ) Methodology Checklist for Cross-Sectional Study

The Agency for Healthcare Research and Quality (AHRQ) Methodology Checklist for Cross-Sectional Study			
Major Components	Response options		
1. Define the source of information (survey, record review)	Yes	No	Unclear
2. List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications	Yes	No	Unclear
3. Indicate time period used for identifying patients	Yes	No	Unclear
4. Indicate whether or not subjects were consecutive if not population-based	Yes	No	Unclear
5. Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants	Yes	No	Unclear
6. Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)	Yes	No	Unclear
7. Explain any patient exclusions from analysis	Yes	No	Unclear
8. Describe how confounding was assessed and/or controlled	Yes	No	Unclear
9. If applicable, explain how missing data were handled in the analysis	Yes	No	Unclear
10. Summarize patient response rates and completeness of data collection	Yes	No	Unclear
11. Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained	Yes	No	Unclear

Table S4. The Newcastle-Ottawa Scale (NOS) for cohort study

The Newcastle-Ottawa Scale (NOS) for cohort study	
Major Components	Response options
Selection	
1. Representativeness of the exposed cohort	
1) truly representative of the average _____ (describe) in the community	☆
2) somewhat representative of the average _____ in the community	☆
3) selected group of users eg nurses, volunteers	/
4) no description of the derivation of the cohort	/
2. Selection of the non exposed cohort	
1) drawn from the same community as the exposed cohort	☆
2) drawn from a different source	/
3) no description of the derivation of the non exposed cohort	/
3. Ascertainment of exposure	
1) secure record (eg surgical records)	☆
2) structured interview <input type="checkbox"/>	☆
3) written self report	/
4) no description	/
4. Demonstration that outcome of interest was not present at start of study	
1) yes	☆
2) no	/
Comparability*	
5. Comparability of cohorts on the basis of the design or analysis	
1) study controls for _____ (select the most important factor)	☆
2) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.)	☆
Outcome	
6. Assessment of outcome	
1) independent blind assessment	☆
2) record linkage	☆

3) self report	/
4) no description	/
7. Was follow-up long enough for outcomes to occur	
1) yes (select an adequate follow up period for outcome of interest)	☆
2) no	/
8. Adequacy of follow up of cohorts	
1) complete follow up - all subjects accounted for ⁻	☆
2) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an adequate %) follow up, or description provided of those lost)	☆
3) follow up rate < ____% (select an adequate %) and no description of those lost	/
4) no statement	/
<p>*, A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories; a maximum of two stars can be given for Comparability.</p>	

Table S5. The Newcastle-Ottawa Scale (NOS) for case-control study

The Newcastle-Ottawa Scale (NOS) for case-control study	
Major Components	Response options
Selection	
1. Is the case definition adequate?	
1) yes, with independent validation	☆
2) yes, eg record linkage or based on self reports	/
3) no description	/
2. Representativeness of the cases	
1) consecutive or obviously representative series of cases	☆
2) potential for selection biases or not stated	/
3. Selection of Controls	
1) community controls	☆
2) hospital controls	/
3) no description	/
4. Definition of Controls	
1) no history of disease (endpoint)	☆
2) no description of source	/
Comparability*	
5. Comparability of cases and controls on the basis of the design or analysis	
1) study controls for _____ (Select the most important factor.)	☆
2) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.)	☆
Exposure	
6. Ascertainment of exposure	
1) secure record (eg surgical records)	☆
2) structured interview where blind to case/control status	☆
3) interview not blinded to case/control status	/
4) written self report or medical record only	/
5) no description	/

<p>7. Same method of ascertainment for cases and controls</p> <p>1) yes</p> <p>2) no</p>	<p>☆</p> <p>/</p>
<p>8. Non-Response rate</p> <p>1) same rate for both groups</p> <p>2) non respondents described</p> <p>3) rate different and no designation</p>	<p>☆</p> <p>/</p> <p>/</p>
<p>*, A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories; a maximum of two stars can be given for Comparability.</p>	

Table S6. The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case series/case reports

The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case series/case reports				
Major Components	Response options			
1. Were patient's demographic characteristics clearly described?	Yes	No	Unclear	Not applicable
2. Was the patient's history clearly described and presented as a timeline?	Yes	No	Unclear	Not applicable
3. Was the current clinical condition of the patient on presentation clearly described?	Yes	No	Unclear	Not applicable
4. Were diagnostic tests or assessment methods and the results clearly described?	Yes	No	Unclear	Not applicable
5. Was the intervention(s) or treatment procedure(s) clearly described?	Yes	No	Unclear	Not applicable
6. Was the post-intervention clinical condition clearly described?	Yes	No	Unclear	Not applicable
7. Were adverse events (harms) or unanticipated events identified and described?	Yes	No	Unclear	Not applicable
8. Does the case report provide takeaway lessons?	Yes	No	Unclear	Not applicable
Overall appraisal: Include <input type="checkbox"/> Exclude <input type="checkbox"/> Seek further info <input type="checkbox"/>				

Table S7. Quality assessment of the included studies*

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Total
The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case series/case reports												
Song et al., 2011	1	0	1	1	0	0	0	1				4
The Agency for Healthcare Research and Quality (AHRQ) Methodology Checklist for Cross-Sectional Study												
Ding et al., 2022	1	1	1	1	1	1	0	0	0	0	1	7
Wang et al., 2017	1	1	1	1	1	1	0	0	0	0	1	7
Wu et al., 2017	1	1	1	1	1	1	0	0	0	1	0	7
Cao et al., 2021	1	1	1	1	1	1	0	0	0	1	0	7
Jiang et al., 2014	1	0	1	1	1	1	0	0	0	0	0	5
Meng et al., 2008	1	0	1	1	1	1	0	0	0	0	1	6
Meng et al., 2018	1	1	1	1	1	1	0	0	0	0	1	7
Yin et al., 2015	1	1	1	1	1	1	0	0	0	0	1	7
Huang et al., 2022	1	1	1	1	1	1	0	0	0	1	0	7
Zhou et al., 2013	1	0	1	1	1	1	0	0	0	0	0	5
Wang et al., 2022	1	0	1	1	1	1	0	0	0	0	1	6
Li et al., 2016	1	0	1	1	1	1	0	0	0	0	0	5
Deng et al., 2013	1	0	1	1	1	1	0	0	0	0	0	5
Wang et al., 2021	1	1	1	1	1	1	0	0	0	0	0	6
Huang et al., 2021	1	0	1	1	1	1	0	0	0	0	0	5
Li, 2018	1	0	1	1	1	1	0	0	0	0	0	5
Zhu et al., 2013	1	1	1	1	1	1	0	0	0	0	0	6
Sun et al., 2019	1	1	1	1	1	1	0	0	0	0	0	6
Wang et al., 2019	1	1	1	1	1	1	0	0	0	1	0	7
Zhang et al., 2021	1	1	1	1	1	1	0	0	0	0	0	6
Li et al., 2018	1	1	1	1	1	1	0	0	0	1	0	7
Liu et al., 2021	1	1	1	1	1	1	0	0	0	0	0	6
Chou et al., 2011	1	1	1	1	1	1	0	0	0	0	0	6
The Newcastle-Ottawa Scale (NOS) for cohort study and case-control study												

R. Lan et al., 2011	1	1	1	1	1	1	1	1				8
Zhang et al., 2011	1	1	1	1	0	1	1	0				6
Tian at al., 2022	1	1	1	1	1	1	1	1				8
Chiang et al., 2020	2	1	0	1	2	2	0	0				8

*Specific numbers Q1-Q11 were shown in Tables S3 to S6 respectively.

Table S8. Subgroup analyses of positive NTM isolates from patients with HIV/AIDS in different region*

Observed indicators	Region	Number of included studies	Sample size	Heterogeneity		MD or PR (95%CI)	Heterogeneity across subgroups	
				P	I ² , %		P	I ² , %
Gender distribution (men)	N	3	109	—	—	0.881 (0.805, 0.943)	0.222	5.7
	S	7	450	0.040	54.6	0.827 (0.765, 0.882)		
	W	5	266	< 0.001	87.3	0.847 (0.699, 0.953)		
	E	6	711	0.001	75.6	0.923 (0.864, 0.968)		
	C	2	36	—	—	0.895 (0.762, 0.984)		
NTM species distribution								
<i>Mycobacterium avium</i> complex	N	2	76	—	—	0.955 (0.909, 1.001)	< 0.001	121.3
	S	5	322	0.822	0.0	0.559 (0.505, 0.614)		
	W	3	193	—	—	0.633 (0.428, 0.839)		
	E	4	243	< 0.001	97.3	0.639 (0.334, 0.943)		
<i>Mycobacterium abscessus</i> complex	S	4	311	0.778	0.0	0.029 (0.011, 0.053)	0.442	3.0
	W	3	193	—	—	0.076 (0.030, 0.139)		
	E	3	141	—	—	0.024 (0.000, 0.115)		
<i>Mycobacterium kansasii</i>	N	1	71	—	—	0.042 (0.009, 0.119)	0.222	2.7
	S	4	311	0.661	0.0	0.074 (0.046, 0.107)		
	W	3	193	—	—	0.139 (0.040, 0.282)		
	E	3	221	—	—	0.088 (0.002, 0.254)		
<i>Mycobacterium gordonae</i>	S	4	311	—	0.0	0.069 (0.041, 0.097)	0.045	6.2
	W	2	134	—	—	0.029 (0.001, 0.057)		
	E	3	221	—	—	0.194 (0.009, 0.379)		
Other NTM species [†]	N	1	5	—	—	0.200 (0.036, 0.624)	< 0.001	28.9

	S	5	322	0.842	0.0	0.262 (0.214, 0.310)		
	W	3	193	—	—	0.090 (0.024, 0.156)		
	E	4	243	0.150	43.5	0.091 (0.039, 0.142)		
Clinical symptoms								
Fever	N	1	71	—	—	0.761 (0.650, 0.845)	0.429	3.8
	S	7	331	0.003	69.2	0.729 (0.641, 0.818)		
	W	3	126	—	—	0.699 (0.578, 0.820)		
	E	2	116	—	—	0.652 (0.567, 0.737)		
	C	3	99	—	—	0.570 (0.280, 0.859)		
Cough or expectoration	N	1	71	—	—	0.338 (0.239, 0.454)	< 0.001	64.4
	S	6	318	< 0.001	93.8	0.705 (0.527, 0.882)		
	W	3	126	—	—	0.884 (0.794, 0.974)		
	E	2	116	—	—	0.577 (0.489, 0.665)		
	C	2	90	—	—	0.520 (0.428, 0.611)		
Dyspnea	N	1	71	—	—	0.127 (0.068, 0.224)	< 0.001	25.7
	S	3	169	—	—	0.457 (0.131, 0.783)		
	W	2	103	—	—	0.403 (0.310, 0.497)		
	C	2	90	—	—	0.151 (0.080, 0.222)		
Abdominal pain or diarrhea	N	1	71	—	—	0.254 (0.167, 0.366)	0.043	8.1
	S	3	169	—	—	0.341 (0.270, 0.412)		
	W	1	59	—	—	0.169 (0.095, 0.285)		
	E	2	116	—	—	0.276 (0.195, 0.357)		
Night sweats	N	1	71	—	—	0.085 (0.039, 0.172)	0.016	12.2
	S	1	82	—	—	0.195 (0.124, 0.294)		
	W	1	23	—	—	0.391 (0.222, 0.592)		
	E	1	94	—	—	0.138 (0.083, 0.222)		

Fatigue	C	2	72	—	—	0.208 (0.114, 0.302)	0.016	12.2
	N	1	71	—	—	0.324 (0.227, 0.439)		
	S	5	282	< 0.001	97.6	0.499 (0.199, 0.799)		
	W	1	59	—	—	0.153 (0.082, 0.265)		
	E	1	94	—	—	0.202 (0.133, 0.294)		
Weight loss	C	2	90	—	—	0.322 (0.226, 0.419)	< 0.001	67.3
	N	1	71	—	—	0.141 (0.078, 0.240)		
	S	5	282	< 0.001	97.4	0.532 (0.231, 0.833)		
	W	2	82	—	—	0.602 (0.520, 0.683)		
	E	2	116	—	—	0.453 (0.363, 0.543)		
Superficial lymphadenectasis	C	2	72	—	—	0.305 (0.199, 0.412)	0.796	1.0
	S	4	182	0.003	78.8	0.386 (0.224, 0.547)		
	W	2	73	—	—	0.472 (0.363, 0.581)		
	E	1	27	—	—	0.407 (0.245, 0.593)		
	C	3	99	—	—	0.388 (0.138, 0.637)		
Laboratory tests								
Hemoglobin count (g/L)	N	2	104	0.001	91.7	85.823 (71.049, 100.597)	0.605	1.0
	S	1	11	—	—	91.790 (72.744, 110.836)		
	E	2	191	< 0.001	92.7	105.250 (68.672, 141.828)		
CD4 ⁺ T cell count (pieces/ μ L)	N	1	33	—	—	112.320 (33.793, 190.847)	0.001	16.6
	S	1	11	—	—	26.460 (5.907, 47.013)		
	W	2	73	0.048	74.4	53.836 (25.340, 82.333)		
	E	2	190	0.088	65.6	11.411 (8.379, 14.442)		
	S	3	103	—	—	0.404 (0.137, 0.671)		
Anemia	W	3	126	—	—	0.803 (0.711, 0.894)	0.011	9.1
	C	1	9	—	—	0.556 (0.267, 0.811)		

CD4 ⁺ T cell count ≤ 50 (pieces/μL)	N	2	76	—	—	0.876 (0.779, 0.953)	0.001	19.1
	S	4	182	0.344	9.8	0.763 (0.693, 0.827)		
	W	2	149	—	—	0.630 (0.550, 0.706)		
	E	2	124	—	—	0.672 (0.586, 0.754)		
	C	3	99	—	—	0.478 (0.235, 0.726)		
CD4 ⁺ T cell count 51-200 (pieces/μL)	N	2	76	—	—	0.109 (0.037, 0.202)	0.002	17.2
	S	4	182	0.545	0.0	0.190 (0.134, 0.251)		
	W	2	149	—	—	0.294 (0.223, 0.370)		
	E	2	124	—	—	0.187 (0.121, 0.262)		
	C	3	99	—	—	0.349 (0.254, 0.450)		
CD4 ⁺ T cell count > 200 (pieces/μL)	N	2	76	—	—	0.000 (0.000, 0.028)	0.016	12.2
	S	4	182	0.284	21.1	0.040 (0.010, 0.083)		
	W	2	149	—	—	0.058 (0.024, 0.103)		
	E	2	124	—	—	0.130 (0.074, 0.198)		
	C	3	99	—	—	0.101 (0.000, 0.394)		

Thoracic imaging manifestations

Distribution of lesions

Single lung involvement	N	1	71	—	—	0.127 (0.060, 0.227)	0.024	9.4
	S	4	149	0.005	76.8	0.182 (0.044, 0.373)		
	W	1	50	—	—	0.160 (0.072, 0.291)		
	E	1	27	—	—	0.000 (0.000, 0.128)		
Bilateral lung involvement	N	1	71	—	—	0.761 (0.645, 0.854)	0.002	14.6
	S	4	149	< 0.001	85.6	0.786 (0.533, 0.964)		
	W	1	50	—	—	0.840 (0.709, 0.928)		
	E	1	27	—	—	1.000 (0.872, 1.000)		
No abnormalities	N	2	104	—	—	0.156 (0.091, 0.234)	< 0.001	18.4

	S	4	149	0.012	72.5	0.012 (0.000, 0.110)		
	W	1	50	—	—	0.000 (0.000, 0.071)		
	E	3	143	—	—	0.219 (0.000, 0.738)		
Changes of lesion morphology and density								
Patchy shadows	N	1	71	—	—	0.423 (0.315, 0.538)	< 0.001	29.4
	S	3	141	—	—	0.498 (0.172, 0.824)		
	W	3	132	—	—	0.481 (0.306, 0.655)		
	E	1	27	—	—	0.074 (0.021, 0.234)		
Nodules	N	2	76	—	—	0.381 (0.273, 0.490)	0.002	15.0
	S	3	141	—	—	0.360 (0.154, 0.567)		
	W	3	132	—	—	0.453 (0.240, 0.665)		
	E	2	121	—	—	0.182 (0.121, 0.243)		
Millet shadow	N	2	104	—	—	0.036 (0.006, 0.085)	0.791	1.0
	S	1	31	—	—	0.065 (0.008, 0.214)		
	W	2	109	—	—	0.067 (0.025, 0.125)		
	E	3	143	—	—	0.030 (0.000, 0.195)		
Cavitary lesion	N	3	109	—	—	0.007 (0.000, 0.078)	0.001	18.6
	S	5	206	< 0.001	90.7	0.221 (0.052, 0.455)		
	W	2	109	—	—	0.137 (0.077, 0.210)		
	E	3	143	—	—	0.061 (0.006, 0.154)		
	C	1	35	—	—	0.343 (0.191, 0.522)		
Stripe shadow	N	2	104	—	—	0.400 (0.307, 0.497)	0.033	8.7
	S	2	110	—	—	0.512 (0.415, 0.608)		
	W	1	50	—	—	0.620 (0.472, 0.753)		
	E	1	27	—	—	0.630 (0.424, 0.806)		
Bronchiectasis	N	1	5	—	—	0.200 (0.036, 0.624)	0.018	11.9

	S	2	110	—	—	0.354 (0.265, 0.443)		
	W	1	50	—	—	0.340 (0.224, 0.478)		
	E	1	27	—	—	0.333 (0.186, 0.522)		
	C	1	27	—	—	0.667 (0.478, 0.814)		
Accompanying Signs								
Thoracic lymph node enlargement	N	2	76	—	—	0.762 (0.648, 0.861)	< 0.001	18.8
	S	4	170	< 0.001	95.4	0.316 (0.030, 0.710)		
	W	2	73	—	—	0.590 (0.473, 0.702)		
	E	1	27	—	—	0.296 (0.138, 0.502)		
Hydropericardium	N	1	71	—	—	0.141 (0.078, 0.240)	0.464	1.5
	S	2	60	—	—	0.079 (0.011, 0.147)		
	W	2	82	—	—	0.127 (0.056, 0.197)		
Hydrothorax	N	1	71	—	—	0.211 (0.123, 0.324)	< 0.001	26.1
	S	2	60	—	—	0.170 (0.082, 0.279)		
	W	3	132	—	—	0.228 (0.019, 0.554)		
	E	3	143	—	—	0.015 (0.000, 0.047)		
	C	1	35	—	—	0.114 (0.032, 0.267)		
Pleural thickening	N	2	76	—	—	0.275 (0.175, 0.375)	0.023	11.4
	S	2	110	—	—	0.149 (0.084, 0.215)		
	W	1	50	—	—	0.080 (0.032, 0.188)		
	E	1	27	—	—	0.074 (0.021, 0.234)		
	C	1	27	—	—	0.111 (0.039, 0.281)		
Treatment outcome								
Symptoms improve‡	N	2	104	—	—	0.732 (0.649, 0.814)	0.202	3.2
	S	3	162	—	—	0.619 (0.397, 0.841)		
	C	1	9	—	—	0.889 (0.565, 0.980)		

Death	N	2	104	—	—	0.036 (0.005, 0.084)	0.136	4.0
	S	3	162	—	—	0.096 (0.053, 0.148)		
	C	1	9	—	—	0.000 (0.000, 0.336)		
Others§	N	2	104	—	—	0.200 (0.127, 0.274)	0.580	1.1
	S	3	162	—	—	0.270 (0.048, 0.491)		
	C	1	9	—	—	0.111 (0.020, 0.435)		

MD – mean deviation, PR – prevalence rate, CI – confidence interval, NTM – nontuberculous mycobacterial, W – western region, E – eastern region, N – northern region, S – southern region, C – central region

*Subgroup analyses were not performed for the number of included studies less than 5. We performed the subgroup analysis using the metaprop functional module, which does not show heterogeneity for the number of included studies less than or equal to 3 per subgroup.

†All other NTM species accounted for less than the above four species.

‡Symptom improve is defined as getting better after treatment during hospitalization.

§Others include automatic discharge, transfer to another hospital, and no apparent improvement.

Table S9. Subgroup analyses of positive NTM isolates from patients with HIV/AIDS in sample size per study*

Observed indicators	Sample size per study	Number of included studies	Sample size	Heterogeneity		MD or PR (95%CI)	Heterogeneity across subgroups	
				P	I ² , %		P	I ² , %
Gender distribution (men)	< 50	13	328	0.002	61.7	0.869 (0.797, 0.930)	0.656	0.2
	≥50	10	1244	< 0.001	84.0	0.873 (0.819, 0.918)		
NTM species distribution								
<i>Mycobacterium avium</i> complex	< 50	7	178	< 0.001	88.4	0.632 (0.444, 0.820)	0.881	0.0
	≥50	7	656	< 0.001	97.1	0.652 (0.473, 0.830)		
<i>Mycobacterium abscessus</i> complex	< 50	5	162	0.288	20.0	0.047 (0.013, 0.095)	0.540	0.4
	≥50	5	483	0.026	63.7	0.040 (0.014, 0.076)		
<i>Mycobacterium kansasii</i>	< 50	4	140	0.143	44.7	0.065 (0.016, 0.136)	0.402	0.7
	≥50	7	656	< 0.001	82.4	0.109 (0.057, 0.174)		
<i>Mycobacterium goodii</i>	< 50	4	140	0.118	48.9	0.074 (0.015, 0.133)	0.646	0.2
	≥50	5	526	< 0.001	87.8	0.094 (0.033, 0.154)		
Other NTM species†	< 50	7	178	0.014	62.4	0.201 (0.106, 0.296)	0.260	1.3
	≥50	6	585	< 0.001	86.2	0.134 (0.066, 0.202)		
Clinical symptoms								
Fever	< 50	10	277	0.139	33.6	0.746 (0.683, 0.808)	0.045	4.0
	≥50	6	466	< 0.001	85.1	0.616 (0.506, 0.727)		
Cough or expectoration	< 50	8	255	< 0.001	88.5	0.714 (0.578, 0.851)	0.476	0.5
	≥50	6	466	< 0.001	97.7	0.617 (0.387, 0.847)		
Dyspnea	< 50	4	143	0.044	62.9	0.374 (0.247, 0.502)	0.773	0.1
	≥50	4	290	< 0.001	97.8	0.327 (0.031, 0.622)		
Abdominal pain or diarrhea	< 50	3	94	—	—	0.297 (0.204, 0.389)	0.590	0.3
	≥50	4	321	0.035	65.1	0.268 (0.220, 0.316)		

Night sweats	< 50	2	32	—	—	0.332 (0.171, 0.493)	0.034	4.5
	≥50	4	310	0.107	50.9	0.148 (0.092, 0.204)		
Fatigue	< 50	4	130	< 0.001	98.0	0.462 (0.028, 0.897)	0.561	0.3
	≥50	6	466	< 0.001	90.6	0.328 (0.196, 0.459)		
Weight loss	< 50	6	157	< 0.001	97.2	0.498 (0.153, 0.844)	0.671	0.6
	≥50	6	466	< 0.001	95.1	0.413 (0.229, 0.597)		
Superficial lymphadenectasis	< 50	7	171	< 0.001	78.8	0.469 (0.313, 0.625)	0.149	2.1
	≥50	3	210	—	—	0.315 (0.177, 0.454)		
Laboratory tests								
Hemoglobin count (g/L)	< 50	3	66	< 0.001	87.9	103.553 (82.393, 124.714)	0.073	3.2
	≥50	2	240	0.002	89.2	82.807 (74.567, 91.046)		
CD4 ⁺ T cell count (pieces/μL)	< 50	4	89	< 0.001	86.7	42.930 (12.320, 73.540)	0.463	0.5
	≥50	2	218	< 0.001	99.8	26.371 (5.498, 58.240)		
Anemia	< 50	6	179	< 0.001	89.7	0.539 (0.328, 0.750)	0.005	7.8
	≥50	1	59	—	—	0.864 (0.755, 0.930)		
CD4 ⁺ T cell count ≤ 50 (pieces/μL)	< 50	7	176	< 0.001	80.7	0.764 (0.590, 0.906)	0.357	0.9
	≥50	6	454	< 0.001	93.0	0.644 (0.469, 0.801)		
CD4 ⁺ T cell count 51-200 (pieces/μL)	< 50	7	176	< 0.001	78.1	0.208 (0.081, 0.368)	0.803	0.1
	≥50	6	454	< 0.001	80.4	0.244 (0.159, 0.340)		
CD4 ⁺ T cell count > 200 (pieces/μL)	< 50	7	176	0.563	0.0	0.006 (0.000, 0.033)	0.068	3.3
	≥50	6	454	< 0.001	89.8	0.094 (0.025, 0.197)		
Thoracic imaging manifestations								
Distribution of lesions								
Single lung involvement	< 50	4	79	< 0.001	87.4	0.120 (0.000, 0.413)	0.961	0.0
	≥50	3	218	—	—	0.142 (0.097, 0.192)		
Bilateral lung involvement	< 50	4	79	< 0.001	91.0	0.852 (0.486, 1.000)	0.921	0.0

	≥50	3	218	—	—	0.822 (0.760, 0.877)		
No abnormalities	< 50	6	134	0.003	72.6	0.075 (0.004, 0.196)	0.875	0.0
	≥50	4	312	< 0.001	98.3	0.112 (0.000, 0.489)		
Changes of lesion morphology and density								
Patchy shadows	< 50	4	94	< 0.001	96.4	0.471 (0.061, 0.880)	0.699	0.2
	≥50	4	277	0.769	0.0	0.389 (0.332, 0.446)		
Nodules	< 50	5	99	0.081	51.8	0.508 (0.364, 0.652)	0.095	2.8
	≥50	5	371	< 0.001	92.8	0.324 (0.164, 0.484)		
Millet shadow	< 50	4	113	0.025	67.8	0.080 (0.009, 0.198)	0.275	1.2
	≥50	4	274	< 0.001	88.7	0.025 (0.000, 0.116)		
Cavitary lesion	< 50	9	231	< 0.001	75.2	0.110 (0.033, 0.216)	0.730	0.1
	≥50	5	371	< 0.001	95.5	0.160 (0.025, 0.373)		
Stripe shadow	< 50	3	73	—	—	0.783 (0.499, 0.975)	0.042	4.1
	≥50	3	218	—	—	0.440 (0.276, 0.611)		
Bronchiectasis	< 50	4	72	0.015	71.4	0.399 (0.188, 0.611)	0.691	0.2
	≥50	2	147	—	—	0.354 (0.276, 0.431)		
Accompanying Signs								
Thoracic lymph node enlargement	< 50	6	128	< 0.001	88.2	0.533 (0.266, 0.791)	0.698	0.2
	≥50	3	218	—	—	0.423 (0.050, 0.860)		
Hydropericardium	< 50	3	83	—	—	0.102 (0.038, 0.166)	0.674	0.2
	≥50	2	130	—	—	0.120 (0.065, 0.176)		
Hydrothorax	< 50	6	167	< 0.001	87.2	0.146 (0.024, 0.331)	0.530	0.4
	≥50	4	274	< 0.001	86.3	0.095 (0.020, 0.213)		
Pleural thickening	< 50	4	72	0.181	38.5	0.138 (0.032, 0.243)	0.777	0.1
	≥50	3	218	—	—	0.159 (0.057, 0.261)		

Treatment outcome								
Symptoms improve†‡	< 50	4	107	< 0.001	89.2	0.721 (0.487, 0.956)	0.668	0.2
	≥ 50	2	168	—	—	0.668 (0.597, 0.739)		
Death	< 50	4	107	0.589	0.0	0.074 (0.026, 0.138)	0.430	0.6
	≥ 50	2	168	—	—	0.062 (0.029, 0.105)		
Others§	< 50	4	107	< 0.001	89.5	0.201 (0.004, 0.398)	0.580	0.3
	≥ 50	2	168	—	—	0.260 (0.194, 0.326)		

MD – mean deviation, PR – prevalence rate, CI – confidence interval, NTM – nontuberculous mycobacterial

*Subgroup analyses were not performed for the number of included studies less than 5. We performed the subgroup analysis using the metaprop functional module, which does not show heterogeneity for the number of included studies less than or equal to 3 per subgroup.

†All other NTM species accounted for less than the above four species.

‡Symptom improve is defined as getting better after treatment during hospitalization.

§Others include automatic discharge, transfer to another hospital, and no apparent improvement.